Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$75.90 USD

75.90
2,859,279

-0.55 (-0.72%)

Updated May 23, 2024 04:00 PM ET

After-Market: $75.91 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

BioMarin Pharmaceutical Inc. [BMRN]

Reports for Purchase

Showing records 801 - 814 ( 814 total )

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 801

08/24/2010

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 802

08/17/2010

Company Report

Pages: 9

Company Acquires Early Stage Drug Candidate for Pompe Disease.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 803

08/03/2010

Company Report

Pages: 10

Q2 Financials Missed And 2010 Guidance Was Lowered. Pipeline Progress: So Far So Good For PEG-PAL.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 804

07/22/2010

Company Report

Pages: 8

Consensus And Comparables: We Believe Q2 Consensus Is Achievable.Is Trading In-Line With Comparables But Getting More Expensive; Fair Value Moves to $26.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 805

07/02/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 806

05/24/2010

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 807

04/30/2010

Company Report

Pages: 10

Q1 Financials Beat By A Penny On The Bottom Line But Product Sales Were Mixed. At First Glance GALNS Data Looks Mixed But May Be Good Enough. Fair Value to $24.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 808

04/21/2010

Company Report

Pages: 10

Consensus And Comparables: We Believe Q1 Consensus Is Somewhat High But Achievable. BMRN Is Trading In-Line With Comparables But Getting More Expensive.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 809

03/26/2010

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 810

03/15/2010

Industry Report

Pages: 37

Biotech Balance Sheet

Provider: Merriman Curhan Ford & Co.

Price: 75.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 811

02/24/2010

Company Report

Pages: 9

2009 Financials: Beat On Top And Bottom Line

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 812

02/05/2010

Company Report

Pages: 9

Positive Preliminary Data on GALNS for MPS IVA; Acquisition of LEAD Therapeutics; 2010 Guidance Issued.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 813

02/01/2010

Company Report

Pages: 10

Consensus And Comparables: We Believe Q4 Consensus Is Achievable And BMRN Is Trading In-Line With Comparables; Fair Value Moves to $23.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 814

01/19/2010

Industry Report

Pages: 38

Life Sciences - Biotechnology - Biotech Balance Sheet

Provider: MERRIMAN CURHAN FORD & CO.

Price: 75.00

Research Provided by a Third Party